• Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466).
  

PubMed=21460823; DOI=10.1038/nmeth.1591
Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Hong H.-J., Nakagawa M., Tanabe K., Tezuka K.-i., Shibata T., Kunisada T., Takahashi M., Takahashi J., Saji H., Yamanaka S.
A more efficient method to generate integration-free human iPS cells.
Nat. Methods 8:409-412(2011)

PubMed=22802639; DOI=10.1073/pnas.1209979109
Kajiwara M., Aoi T., Okita K., Takahashi R., Inoue H., Takayama N., Endo H., Eto K., Toguchida J., Uemoto S., Yamanaka S.
Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells.
Proc. Natl. Acad. Sci. U.S.A. 109:12538-12543(2012)

PubMed=24259714; DOI=10.1073/pnas.1319061110
Koyanagi-Aoi M., Ohnuki M., Takahashi K., Okita K., Noma H., Sawamura Y., Teramoto I., Narita M., Sato Y., Ichisaka T., Amano N., Watanabe A., Morizane A., Yamada Y., Sato T., Takahashi J., Yamanaka S.
Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.
Proc. Natl. Acad. Sci. U.S.A. 110:20569-20574(2013)

PubMed=27476965; DOI=10.1016/j.stem.2016.06.019
Nishizawa M., Chonabayashi K., Nomura M., Tanaka A., Nakamura M., Inagaki A., Nishikawa M., Takei I., Oishi A., Tanabe K., Ohnuki M., Yokota H., Koyanagi-Aoi M., Okita K., Watanabe A., Takaori-Kondo A., Yamanaka S., Yoshida Y.
Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity.
Cell Stem Cell 19:341-354(2016)

PubMed=28445466; DOI=10.1038/nature22312
Merkle F.T., Ghosh S., Kamitaki N., Mitchell J., Avior Y., Mello C., Kashin S., Mekhoubad S., Ilic D., Charlton M., Saphier G., Handsaker R.E., Genovese G., Bar S., Benvenisty N., McCarroll S.A., Eggan K.C.
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
Nature 545:229-233(2017)